Ladenburg Thalmann & Co. maintained a Buy rating on 4d Pharma (LBPS – Research Report), with a price23 Mar 2022 10:08
Ladenburg Thalmann & Co. Maintains a Buy Rating on 4d Pharma (LBPS)
Christine Brown
Christine Brown
Jan 20, 2022, 11:45 AM
A
A
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on 4d Pharma (LBPS – Research Report), with a price target of $35.00. The company’s shares closed last Wednesday at $4.35, close to its 52-week low of $4.25.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of 4.8% and a 31.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 4d Pharma with a $35.00 average price target.
https://www.tipranks.com/news/blurbs/ladenburg-thalmann-co-maintains-a-buy-rating-on-4d-pharma-lbps